

Supplementary Online Content

Flaig TW, Plets M, Hussain MHA, et al. Abiraterone acetate for metastatic prostate cancer in patients with suboptimal biochemical response to hormone induction. *JAMA Oncol*. Published online March 30, 2017.
doi:10.1001/jamaoncol.2017.0231

eTable. Adverse Events

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Adverse Events

ADVERSE EVENTS	Abiraterone Acetate (n=40)					
	0	Grade	2	3	4	5
ALT increased	32	4	2	1	1	0
AST increased	31	7	0	2	0	0
Anorexia	38	1	0	1	0	0
Hyperglycemia	30	8	0	2	0	0
Hypertension	30	2	6	2	0	0
Hypokalemia	36	2	0	2	0	0
INR increased	39	0	0	1	0	0
Leukocytosis	39	0	0	1	0	0
Lung infection	38	0	1	1	0	0
Nausea	35	3	0	2	0	0
Rectal hemorrhage	39	0	0	0	1	0
Thromboembolic event	39	0	0	1	0	0
Vomiting	38	0	0	2	0	0
Weight gain	37	2	0	1	0	0
MAX. GRADE ANY ADVERSE EVENT	3	11	13	11	2	0

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio.